<DOC>
	<DOCNO>NCT01079117</DOCNO>
	<brief_summary>To compare effectiveness slow release oral morphine treatment patient previously treat methadone</brief_summary>
	<brief_title>Morphine Slow-release Capsules Substitution Therapy</brief_title>
	<detailed_description>The objective study compare effectiveness slow-release oral morphine ( SROM ) treatment patient previously treat methadone . Efficacy assessed frequency by-consumption illicit substance . The primary efficacy endpoint study proportion positive urine test by-consumption target substance per subject . Target substance define opioids except study drug . The proportion compare substitution methadone SROM treatment crossover design . The secondary endpoint : 1 . The effect SROM retention rate . 2 . By-consumption drug ( cocaine , alcohol , cannabis , benzodiazepine ) . 3 . Occurring psychopathological somatic symptom . 4 . Effect treatment ECG ( QTc prolongation ) . 5 . Group characterisation patient keen change medication . 6 . The change dosage treatment time . 7 . Self-assessed craving Opioids . 8 . Self-assessed satisfaction treatment . 9 . Nature , frequency severity occur adverse event two treatment group . 10 . Assessment safety parameter . Study Design ( Methodology ) : This multicentre , multinational phase III study . It conduct use randomise , open label cross-over design . The subject randomise either 10 week treatment methadone SROM . After adjustment phase one week first medicate 10 week treatment SUB9001 - Integrated Study Protocol 9/58 June 13 , 2009 randomise . The cross-over , subject change opposite treatment , serve additional adjustment phase one week . After second new adjustment phase treat 10 week newly adjust medication . After end week 22 participant continue switch back SROM another 6 month ( week 23 47 ) .</detailed_description>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Inclusion criterion : Minimum age : 18 year Fixed abode At least 26 week treatment ( date ) receive minimum dose 50 mg methadone ≥ 25 mg/day levomethadone inclusion . Patients levomethadone must inform agree switch methadone Mature capable act responsibly , possession mental faculty Female subject must negative urine pregnancy test record prior first dose study medication regular negative urine pregnancy test every 4 week . SUB9001 Integrated Study Protocol 10/58 June 13 , 2009 Hormonal contraception ( oral , transdermal , vaginal , intrauterine subcutaneous ) woman childbearing age No intention reduce substitute medication trial Acceptance trial rule regulation Acceptance participate study . Exclusion criterion : ( Desired ) pregnancy trial Breastfeeding woman Grave acute somatic illness ( e.g . cardiovascular , serious kidney liver affection ( ALAT ASAT &gt; 5x augment ) ) somatic disorder If suffer severe unstable mental health problem If MAOInhibitors take Intracranial injury Intracranial hypertension History epilepsy Severe chronic obstructive lung disease Chronic respiratory failure Known hypersensitivity morphine methadone Pancreatitis Paralytic ileus Baseline QTc interval great 450 msec Long QT Syndrome Patients participate another clinical research study involve new chemical entity within 3 month study entry Patients pending imprisonment time inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Opiate</keyword>
	<keyword>Methadone</keyword>
	<keyword>Slow Release Oral Morphine ( SORM )</keyword>
	<keyword>Sevre-Long™</keyword>
</DOC>